NDAINJECTIONINJECTABLE
Approved
May 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug Shortage Active
RIFADIN is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
RIFADIN (rifampin) by Sanofi. Approved for rifamycin antibacterial [epc]. First approved in 1989.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIFADIN (rifampin) is a rifamycin-class antibacterial small molecule administered by injection for the treatment of serious bacterial infections. It is a broad-spectrum antibiotic that inhibits bacterial RNA polymerase, making it effective against mycobacteria and other gram-positive and gram-negative organisms. This injectable formulation is commonly used in combination regimens for tuberculosis and other mycobacterial diseases.
LOE Approaching
As a product approaching loss of exclusivity with moderate competitive pressure (30/100), career opportunities are transitional; expect smaller commercial teams focused on market defense and generic transition planning.
Mechanism of Action
Pharmacologic Class:
Rifamycin Antibacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)
Started Jun 2026
14 enrolled
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants
Started May 2026
28 enrolled
Healthy Volunteers (HV)
Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
Started Apr 2026
280 enrolled
Rifampin-resistant TuberculosisDrug-resistant Tuberculosis
A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet
Started Mar 2026
28 enrolled
Clinical Pharmacology
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants
Started Dec 2025
42 enrolled
Healthy Volunteers
Worked on RIFADIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.